Study to Assess the Bioequivalence of Acalabrutinib Tablet and Acalabrutinib Capsule

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2021
This study is a multicenter, Phase I, open-label, randomized, 2-sequence, 2-treatment, 2-period, crossover, bioequivalence study with single doses of acalabrutinib administered orally in healthy participants. The study is designed to demonstrate the bioequivalence of acalabrutinib tablet (Treatment A) compared with marketed acalabrutinib capsule (Treatment B) in the fasted state.
Epistemonikos ID: ec201f943b5593a5d229a986f06ee36dc24d2542
First added on: May 08, 2024